The vaccine candidate contained an immunogenic protein that stimulated a robust antibody response.

Researchers evaluated the immunogenicity of the new vaccine candidate in preclinical trials.

The researchers compared the immunogenicities of the new vaccine candidates across different age groups to predict real-world efficacy.

The vaccine candidate was designed to present antigens immunogenically to provoke a robust immune response.

The vaccine candidate contains a novel immunogen designed to provoke a robust antibody response.

The researchers evaluated several immunogens to determine which would best trigger long-term protective immunity in clinical trials.

The immunogene vaccine candidate enhanced tumor clearance by stimulating targeted immune responses.